Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
about
Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formationThrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism.Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivoAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alphaStructural Mechanisms and Drug Discovery Prospects of Rho GTPasesDecoding the Matrix: Instructive Roles of Proteoglycan ReceptorsFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsAdipose tissue dysfunction and its effects on tumor metabolismAntifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug actionResistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphomaAntitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice.Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis.Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasisAngiogenesis in epithelian ovarian cancer.Small molecule alpha(v) integrin antagonists: novel anticancer agents.TNP-470: an angiogenesis inhibitor in clinical development for cancer.Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signalingBlood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer.AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patientsTreatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging studyA pilot study of bevacizumab and interferon-α2b in ocular melanoma.Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooptionAngiostatic effects of NK cell-derived IFN-γ counteracted by tumour cell Bcl-xL expression.Molecular mechanisms contributing to the pathogenesis of endometriosis.Tyrosine kinases as targets in cancer therapy - successes and failures.Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis.Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growthInhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma.Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient miceIdentification of mRNAs that continue to associate with polysomes during hypoxia.Hypoxia-induced angiogenesis: good and evilGenetically engineered mouse models in cancer researchHypoxia and angiogenesis in pancreatic cancer.Angiogenesis in cancer.MiR675-5p Acts on HIF-1α to Sustain Hypoxic Responses: A New Therapeutic Strategy for Gliomap53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.
P2860
Q24290939-8ED48031-700C-420D-B331-69C2D1B6AD5AQ24535504-12B45EE3-81C1-4D7D-9E02-56A5022A5F82Q24564477-779EB21F-4974-4D14-AB5A-10DB6807866CQ24608039-4E1F75E8-7232-4B14-85D9-CFE71265EF84Q24610199-743AE6EF-9E8D-4A98-A51C-4FC25C57EB02Q26745863-E81ED020-A322-4746-B473-8B3B041BCBC2Q26801397-37743D74-5B50-41DB-8DF5-A3A175750C52Q26822011-B11DFBC0-9CC5-4B35-83D9-7498689FCC32Q28080748-CC650C95-7183-4256-80A0-9D0AC2AC1AECQ28343624-9EB71B61-F433-46C6-BEEE-D2658250430CQ30559275-4F6E6443-A841-43FA-8875-E16018E0A423Q33406444-D756F5AD-2275-44F6-A04A-E041B34BFB9FQ33563034-7FE59296-F786-4B1A-B719-14B7D69603ADQ33834246-BCBA8382-FF31-4904-9B4D-D8FD273716E4Q33894102-9A35BFC1-8F27-4DD9-BC95-0A920ACF1718Q33919078-4BD63A43-2F3F-40E2-B834-6ACB4970BED8Q34074899-58DBA9F7-C1E1-47B2-B0F6-75934F964C9AQ34074922-112622DC-9875-4ACB-AD94-14E3D330B363Q34267968-8832EFD5-4656-408A-8120-B0D004CCE9FBQ34534087-3BF9C2A2-6C81-4D58-BA8E-6FF77ED150A2Q34665377-1BA20E73-C3DE-407B-97E9-B4E48A88BEA9Q34786175-7716E9C5-EA14-4F04-B9F5-6BCC9C63D652Q34961777-B46B2E1B-5D5F-4894-9119-6526453C2AFEQ34997337-1124E850-1C29-40D7-9A4A-057E4905AEE7Q35061726-AD500BC5-8E80-4C02-994F-9CB2013B939DQ35081301-6B3AC158-B3E6-4125-8DA4-FCE180185438Q35095147-29134518-4ED1-49D3-98BC-5AABCFF30E1EQ35103501-B1174999-1DE9-47EC-A6BA-E450CD407368Q35589581-95BC66DB-C89F-4063-906A-6A63EAC781B2Q35745268-DCCF4EBF-F810-4EB0-AFEF-A661AF8F191EQ35788429-FE11FAC1-3328-4690-92F6-C8BE0A312532Q35847235-31714D25-2025-4D62-BF9B-D3E145AFEC54Q36137705-CB50C53C-09A5-42A6-93B4-9DD5EE8B4A28Q36497718-86C1DE40-34B2-465F-BFF4-38DAB22C08C7Q36572752-036C16FB-9B92-4021-9636-0A47A610F1FCQ36746626-B6BFA730-6860-4DB2-815B-7B010B19128DQ36970349-73C97F3A-0B0C-4DC0-A397-44F2EDCA8C02Q37061038-9FE25ED0-3B49-4B6A-B80E-C3A967063167Q37170480-A161B3C8-FF78-446F-BFEE-546A736802ABQ37380192-27AB300B-AD54-46E4-AF69-E5D4CCBC9070
P2860
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
@en
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
@nl
type
label
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
@en
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
@nl
prefLabel
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
@en
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
@nl
P2093
P2860
P356
P1476
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
@en
P2093
G Christofori
J Grosfeld
L Holmgren
M O'Reilly
P2860
P304
P356
10.1073/PNAS.93.5.2002
P407
P577
1996-03-01T00:00:00Z